(19)
(11) EP 3 504 187 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.03.2025 Bulletin 2025/13

(45) Mention of the grant of the patent:
19.02.2025 Bulletin 2025/08

(21) Application number: 17844433.7

(22) Date of filing: 24.08.2017
(51) International Patent Classification (IPC): 
A61K 31/451(2006.01)
A61P 25/14(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/451; A61P 25/14
(86) International application number:
PCT/US2017/048461
(87) International publication number:
WO 2018/039477 (01.03.2018 Gazette 2018/09)

(54)

USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE

VERWENDUNG VON PRIDOPIDIN ZUR BEHANDLUNG VON FUNKTIONALEM VERFALL

UTILISATION DE LA PRIDOPIDINE POUR LE TRAITEMENT DU DÉCLIN FONCTIONNEL


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 24.08.2016 US 201662379175 P
15.09.2016 US 201662395263 P
21.10.2016 US 201662411511 P
02.11.2016 US 201662416685 P

(43) Date of publication of application:
03.07.2019 Bulletin 2019/27

(60) Divisional application:
25152698.4 / 4516356

(73) Proprietor: Prilenia Neurotherapeutics Ltd.
6097200 Yakum (IL)

(72) Inventors:
  • HAYDEN, Michael
    Petach Tikva 49131 (IL)
  • PAPAPETROPOULOS, Spyridon
    Wellesley Hills MA 02481 (US)
  • SAVOLA, Juha-Matti
    4153 Reinach (CH)
  • EYAL, Eli
    Petah-Tikva 4932111 (IL)
  • BOROWSKY, Beth
    Flemington NJ 08822 (US)
  • GRACHEV, Igor, D.
    Millstone Twp NJ 08535 (US)

(74) Representative: Pearl Cohen Zedek Latzer Baratz UK LLP 
The Gridiron Building One Pancras Square
London N1C 4AG
London N1C 4AG (GB)


(56) References cited: : 
WO-A1-2011/107583
WO-A1-2016/138130
US-A1- 2010 167 286
WO-A1-2013/086425
US-A1- 2006 287 299
US-A1- 2014 378 508
   
  • KIEBURTZ K D: "A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease", MOVEMENT DISORDERS, vol. 28, no. 10, 28 February 2013 (2013-02-28), US, pages 1407 - 1415, XP093142858, ISSN: 0885-3185, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmds.25362> DOI: 10.1002/mds.25362
  • GARCIA DE YEBENES JUSTO ET AL: "Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial", THE LANCET NEUROLOGY, vol. 10, no. 12, 7 November 2011 (2011-11-07), pages 1049 - 1057, XP093142840, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S1474442211702332?via%3Dihub> DOI: 10.1016/S1474-
  • FERDINANDO SQUITIERI ET AL: "Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date", DRUG DESIGN, DEVELOPMENT AND THERAPY, 28 October 2015 (2015-10-28), United Kingdom, pages 5827, XP055485261, ISSN: 1177-8881, DOI: 10.2147/DDDT.S65738
  • ZIELONKA DANIEL ET AL: "Update on Huntington's disease: Advances in care and emerging therapeutic options", PARKINSONISM AND RELATED DISORDERS, vol. 21, no. 3, 19 December 2014 (2014-12-19), pages 169 - 178, XP029200000, ISSN: 1353-8020, DOI: 10.1016/J.PARKRELDIS.2014.12.013
  • ANON: "Unified Huntington's Disease Rating Scale: Reliability and-Consis tenc y", MOVEMENT DISORDERS, vol. 11, no. 2, 1 January 1996 (1996-01-01), pages 136 - 142, XP055677965
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).